Daniel D Von Hoff
Overview
Explore the profile of Daniel D Von Hoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
215
Citations
13766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benjamin D, Von Hoff D
Cancer Drug Resist
. 2025 Feb;
7:49.
PMID: 39931650
With the growing incidence of obesity-related malignancies, glucagon-like peptide-1 (GLP-1) receptor agonists represent an intriguing potential clinical avenue for cancer prevention and treatment. Population-based data suggest that individuals who have...
2.
Chung V, Alistar A, Becerra C, Kasi A, Borazanci E, Jameson G, et al.
Oncologist
. 2025 Jan;
30(1).
PMID: 39846984
Lessons Learned: Intravenous paricalcitol did not improve the efficacy of pembrolizumab, likely related to the short half-life. Background: Immunotherapy has limited benefit in the treatment of advanced pancreatic cancer with...
3.
Jameson G, Cooper C, Snyder C, Buchanan S, Strelish T, Shearon T, et al.
Oncologist
. 2024 Oct;
29(12):1095-e1778.
PMID: 39436905
Background: Chemotherapy-induced peripheral neuropathy (CIPN), a common problem, can impair function and quality of life in patients, potentially limiting chemotherapy and adversely affecting outcomes. Methods: This trial compared investigational hand...
4.
Jones P, Von Hoff D
Mol Cancer Ther
. 2024 Oct;
24(3):345-353.
PMID: 39363636
The liver is an immune-tolerant organ, allowing for organ transplantation with less immune suppression compared with other organs. It also provides fertile soil for tumor metastases, which tend to be...
5.
Chand D, Savitsky D, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P, et al.
Cancer Discov
. 2024 Jul;
14(12):2407-2429.
PMID: 39083809
This study reveals that Fc-enhanced anti-CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti-CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a...
6.
Arias-Lorza A, Costello J, Hingorani S, Von Hoff D, Korn R, Raghunand N
Sci Rep
. 2024 May;
14(1):11570.
PMID: 38773189
Pre-clinical and clinical studies have shown that PEGPH20 depletes intratumoral hyaluronic acid (HA), which is linked to high interstitial fluid pressures and poor distribution of chemotherapies. 29 patients with metastatic...
7.
Liang G, Oh T, Hah N, Tiriac H, Shi Y, Truitt M, et al.
Nat Commun
. 2023 Dec;
14(1):7791.
PMID: 38057326
Oncogenic lesions in pancreatic ductal adenocarcinoma (PDAC) hijack the epigenetic machinery in stromal components to establish a desmoplastic and therapeutic resistant tumor microenvironment (TME). Here we identify Class I histone...
8.
Rossi G, Jensen A, Ng S, Yin Z, Li A, Misra A, et al.
Sci Rep
. 2023 Oct;
13(1):16953.
PMID: 37805542
SIWA318H is a novel monoclonal antibody that selectively targets an advanced glycation end product biomarker found in damaged/dysfunctional cells exhibiting (a) aerobic glycolysis, and (b) oxidative stress. Cells with this...
9.
Rajbhandari N, Hamilton M, Quintero C, Ferguson L, Fox R, Schurch C, et al.
Cancer Cell
. 2023 Oct;
41(11):1989-2005.e9.
PMID: 37802055
Identifying the cells from which cancers arise is critical for understanding the molecular underpinnings of tumor evolution. To determine whether stem/progenitor cells can serve as cells of origin, we created...
10.
Liang G, Oh T, Hah N, Tiriac H, Shi Y, Truitt M, et al.
bioRxiv
. 2023 Sep;
PMID: 37745372
Oncogenic lesions in pancreatic ductal adenocarcinoma (PDAC) hijack the epigenetic machinery in stromal components to establish a desmoplastic and therapeutic resistant tumor microenvironment (TME). Here we identify Class I histone...